UNMC Department of Internal Medicine personnel and other colleagues gathered at the Wigton Heritage Center Dec. 2 to wish Julie Vose, MD, success as she transitions from the chief of the UNMC Division of Oncology and Hematology to become director of the Lymphoma Research Group.
Mark Rupp, MD, interim chair of internal medicine, called Dr. Vose, and faculty and staff like her, “the bedrock, the foundation upon which UNMC and Nebraska Medicine are built.”
Dr. Rupp praised Dr. Vose for being the architect of the oncology and hematology division. Following in the footsteps of other tremendous role models, he said, she committed to UNMC and continued the division’s upward trajectory.
Dr. Vose’s choice of UNMC was an impactful one. Under her leadership, the oncology and hematology division grew to approximately 36 faculty, 12 fellows, 26 advanced practice providers and numerous research, educational and administrative staff, Dr. Rupp said.
“Oncology/hematology is perennially in the top one or two divisions in the internal medicine department in terms of extramural funding and peer-reviewed publication,” he said.
Brad Britigan, MD, dean of the UNMC College of Medicine, extolled Dr. Vose’s leadership, pointing to the growth of the division over the past 24 years. He also noted her individual contributions and excellence in the clinical and research areas of lymphoma, as well as her mentorship of faculty.
Other speakers at the event, which was attended by approximately 70 people, included Michael Ash, MD, CEO of Nebraska Medicine; and Matthew Lunning, MD, a longtime colleague who currently is serving as the interim chief of the UNMC Division of Hematology.
“We are all fortunate that Dr. Vose chose to stay here at UNMC, and we thank her and celebrate her incredible career success,” Dr. Rupp said.
